FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112560948> ?p ?o ?g. }

• W2112560948 endingPage "1009" @default.
• W2112560948 startingPage "1001" @default.
• W2112560948 abstract "Background: Results from preclinical studies have suggested that the organosulfur compound anethole dithiolethione (ADT) may be an effective chemopreventive agent for lung cancer. We conducted a phase IIb study to determine the effects of ADT in smokers with bronchial dysplasia. Methods: One hundred twelve current and former smokers with a smoking history of at least 30 pack-years and at least one site of bronchial dysplasia identified by an autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive placebo or ADT at 25 mg orally thrice daily for 6 months. Each subject then underwent a follow-up bronchoscopy-directed biopsy. We used changes in histopathologic grade and nuclear morphometry index (MI) as the primary and secondary end point biomarkers, respectively. Chi-square tests with continuity correction were used to compare response rates on a lesion- and person-specific basis between the two study groups. All statistical tests were two-sided. Results: One hundred one subjects had a follow-up bronchoscopy. In the lesion-specific analysis, progression rate of pre-existing dysplastic lesions by two or more grades and/or the appearance of new lesions was statistically significantly lower in the ADT group (8%) than in the placebo group (17%) (P<.001; difference = 9%, 95% confidence interval [CI] = 4% to 15%). In the person-specific analysis, the disease progression rate was statistically significantly lower in the ADT group (32%) than in the placebo group (59%) (P = .013; difference = 27%, 95% CI = 6% to 48%). The two treatment groups did not differ statistically significantly in terms of nuclear MI. Among individuals with an abnormal nuclear MI before treatment (29 in the ADT group and 25 in the placebo group), the progression rate in the ADT group (41%) was substantially lower than that in the placebo group (60%), although the difference was not statistically significant (P = .28; difference = 19%, 95% CI = –11% to 49%). Adverse events were mostly minor gastrointestinal symptoms that resolved with dose reduction or discontinuation of the medication. Conclusion: Our results suggest that, in smokers, ADT is a potentially efficacious chemoprevention agent for lung cancer." @default.
• W2112560948 created "2016-06-24" @default.
• W2112560948 creator A5014634853 @default.
• W2112560948 creator A5015008352 @default.
• W2112560948 creator A5015304965 @default.
• W2112560948 creator A5023271820 @default.
• W2112560948 creator A5031888358 @default.
• W2112560948 creator A5037959555 @default.
• W2112560948 creator A5059166265 @default.
• W2112560948 creator A5074008006 @default.
• W2112560948 creator A5081838594 @default.
• W2112560948 date "2002-07-03" @default.
• W2112560948 modified "2023-10-16" @default.
• W2112560948 title "A Randomized Phase IIb Trial of Anethole Dithiolethione in Smokers with Bronchial Dysplasia" @default.
• W2112560948 cites W1224318197 @default.
• W2112560948 cites W1492846117 @default.
• W2112560948 cites W1515802929 @default.
• W2112560948 cites W1539003378 @default.
• W2112560948 cites W1556877038 @default.
• W2112560948 cites W1584378357 @default.
• W2112560948 cites W172541795 @default.
• W2112560948 cites W1963901314 @default.
• W2112560948 cites W1967020114 @default.
• W2112560948 cites W1967718615 @default.
• W2112560948 cites W1978052764 @default.
• W2112560948 cites W1979892584 @default.
• W2112560948 cites W1988354675 @default.
• W2112560948 cites W1994734462 @default.
• W2112560948 cites W1997063587 @default.
• W2112560948 cites W1998982181 @default.
• W2112560948 cites W2014053256 @default.
• W2112560948 cites W2035665701 @default.
• W2112560948 cites W2042917615 @default.
• W2112560948 cites W2055825222 @default.
• W2112560948 cites W2059972525 @default.
• W2112560948 cites W2103602077 @default.
• W2112560948 cites W2118963481 @default.
• W2112560948 cites W2140394683 @default.
• W2112560948 cites W2145584839 @default.
• W2112560948 cites W2150617732 @default.
• W2112560948 cites W2152404909 @default.
• W2112560948 cites W2153003314 @default.
• W2112560948 cites W2176891727 @default.
• W2112560948 cites W2184431203 @default.
• W2112560948 cites W2189232079 @default.
• W2112560948 cites W2312609348 @default.
• W2112560948 cites W2411931087 @default.
• W2112560948 cites W2489093462 @default.
• W2112560948 cites W46099888 @default.
• W2112560948 cites W583307094 @default.
• W2112560948 cites W8861192 @default.
• W2112560948 cites W3011771670 @default.
• W2112560948 doi "https://doi.org/10.1093/jnci/94.13.1001" @default.
• W2112560948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12096085" @default.
• W2112560948 hasPublicationYear "2002" @default.
• W2112560948 type Work @default.
• W2112560948 sameAs 2112560948 @default.
• W2112560948 citedByCount "134" @default.
• W2112560948 countsByYear W21125609482012 @default.
• W2112560948 countsByYear W21125609482013 @default.
• W2112560948 countsByYear W21125609482014 @default.
• W2112560948 countsByYear W21125609482015 @default.
• W2112560948 countsByYear W21125609482016 @default.
• W2112560948 countsByYear W21125609482017 @default.
• W2112560948 countsByYear W21125609482018 @default.
• W2112560948 countsByYear W21125609482019 @default.
• W2112560948 countsByYear W21125609482020 @default.
• W2112560948 countsByYear W21125609482021 @default.
• W2112560948 countsByYear W21125609482022 @default.
• W2112560948 countsByYear W21125609482023 @default.
• W2112560948 crossrefType "journal-article" @default.
• W2112560948 hasAuthorship W2112560948A5014634853 @default.
• W2112560948 hasAuthorship W2112560948A5015008352 @default.
• W2112560948 hasAuthorship W2112560948A5015304965 @default.
• W2112560948 hasAuthorship W2112560948A5023271820 @default.
• W2112560948 hasAuthorship W2112560948A5031888358 @default.
• W2112560948 hasAuthorship W2112560948A5037959555 @default.
• W2112560948 hasAuthorship W2112560948A5059166265 @default.
• W2112560948 hasAuthorship W2112560948A5074008006 @default.
• W2112560948 hasAuthorship W2112560948A5081838594 @default.
• W2112560948 hasBestOaLocation W21125609481 @default.
• W2112560948 hasConcept C126322002 @default.
• W2112560948 hasConcept C141071460 @default.
• W2112560948 hasConcept C142724271 @default.
• W2112560948 hasConcept C168563851 @default.
• W2112560948 hasConcept C204787440 @default.
• W2112560948 hasConcept C27081682 @default.
• W2112560948 hasConcept C2775894508 @default.
• W2112560948 hasConcept C2775934546 @default.
• W2112560948 hasConcept C2776256026 @default.
• W2112560948 hasConcept C2778996910 @default.
• W2112560948 hasConcept C44249647 @default.
• W2112560948 hasConcept C71924100 @default.
• W2112560948 hasConcept C90924648 @default.
• W2112560948 hasConceptScore W2112560948C126322002 @default.
• W2112560948 hasConceptScore W2112560948C141071460 @default.
• W2112560948 hasConceptScore W2112560948C142724271 @default.
• W2112560948 hasConceptScore W2112560948C168563851 @default.

• next